We considered manipulating the ethyl acetohydroxamate functionality in ethyl acetohydroxamate chalcones by introducing an oxime to produce a range of novel chalcone oxime ethers (COEs) with the objective of synthesizing drugs with MAO and AChE inhibitory effects for the treatment of AD since oxime ethers have numerous biological properties and ethyl acetohydroxamate chalcones have significant MAO-B and AChE inhibitory [37] (Figure 2) and antiplasmodial [45] effects. Here, MAOB is linked to Alzheimer disease.